1 – 21 of 21
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Reduced Intensity transplantation vs chemotherapy in CR1. A prospective, pseudorandomized study in 50–70 year old AML patients
(
- Contribution to journal › Article
- 2023
-
Mark
Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
(
- Contribution to journal › Article
- 2022
-
Mark
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
(
- Contribution to journal › Article
- 2021
-
Mark
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? : A population-based study
(
- Contribution to journal › Article
-
Mark
Clinical and genomic characterization of patients diagnosed with the provisional entity Acute myeloid leukemia with BCR-ABL1, a Swedish population-based study
(
- Contribution to journal › Article
- 2020
-
Mark
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997–2014 : improving performance status is a major contributing factor
(
- Contribution to journal › Letter
-
Mark
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
(
- Contribution to journal › Article
-
Mark
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years
(
- Contribution to journal › Letter
- 2019
-
Mark
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
(
- Contribution to journal › Article
-
Mark
Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period
(
- Contribution to journal › Letter
- 2018
-
Mark
Acute myeloid leukemia in very old patients
(
- Contribution to journal › Article
- 2017
-
Mark
NOX2-dependent immunosuppression in chronic myelomonocytic leukemia
(
- Contribution to journal › Article
-
Mark
Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia : A population-based study from the Swedish AML registry
(
- Contribution to journal › Article
- 2015
-
Mark
Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
(
- Contribution to journal › Article
-
Mark
Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.
(
- Contribution to journal › Article
- 2011
-
Mark
Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006.
(
- Contribution to journal › Article
-
Mark
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
(
- Contribution to journal › Article
- 2009
-
Mark
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
(
- Contribution to journal › Article
-
Mark
Proportion of Adult AML Patient Population Receiving Allogeneic Stem Cell Transplantation and Long-Term Outcome: Real World Data From the Swedish National Acute Leukemia Registry.
(
- Contribution to journal › Published meeting abstract
-
Mark
Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
(
- Contribution to journal › Published meeting abstract